Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
... reported, neutropenia was the dose limiting
toxicity when used as a single agent.
"In both ... studies pixantrone exhibited lower cardiac
toxicity and better anti-tumor activity than that observed ... as it is devoid of the putative cardiac
toxicity generating chemical structure," said Barry W. ...
Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer
... MDX-1110 showed a favorable safety and
toxicity profile. MDX-1110 also demonstrated potent ... treatment for liver cancer.
Efficacy and
toxicity of anti-mesothelin antibody drug conjugate ... a cleavable linker also showed a more favorable
toxicity and safety profile over conjugates using a ...
Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma
... of prostaglandin
analogues: an in vivo
toxicity assay" at the 9th Scientific Meeting of ... studies
confirmed the ocular surface
toxicity of anti-glaucomatous eye drops
containing ... importance taken into account that
BAK exerts
toxicity after long term use and that glaucoma is a ...
Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
... breast cancer, but
concerns about cardiac
toxicity have prevented oncologists from using them ... continued until an unacceptable
treatment-related
toxicity or disease progression occurred.
The ... of total cumulative dose
- Cardiac
toxicity may also occur at lower cumulative doses (400
...
BioNumerik Pharmaceuticals Observes Evidence of a Survival Increase in Lung Cancer Patients Participating in Tavocept(TM) Clinical Trial
... reduction in chemotherapy-induced
renal (kidney)
toxicity and nausea/vomiting was also observed in ... in the Tavocept group with no dose limiting
toxicity observed
for Tavocept in either trial. These ... without any substantial dose-limiting
toxicity of its own.
Based on these results, we are ...
Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
... signals of clinical activity and
acceptable
toxicity with this combination.
Picoplatin, the ... both agents
could be combined with an acceptable
toxicity profile," said Don S. Dizon,
M.D., assistant ... cancer). Hematologic and non-hematologic
toxicity were mild. This
study suggests that picoplatin ...
Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
... cycles of picoplatin therapy.
The dose limiting
toxicity (DLT) for the every-four-week regimen at ... in multiple indications with less severe
kidney
toxicity (nephrotoxicity) and nerve
toxicity (neurotoxicity) than is
commonly observed with ...
Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
... was accepted for publication:
-- Activity and
toxicity of Pegylated Liposomal Doxorubicin in ... of total cumulative dose -- Cardiac
toxicity may also occur at lower cumulative doses ... -- In patients with multiple myeloma, hematologic
toxicity (based on platelet count, absolute ...
Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
... Candidate, RDEA806, Demonstrated No Reproductive
toxicity in Preclinical Study -
... causative agent of
AIDS.
Animal reproductive
toxicity studies recently completed with RDEA806
have ... other HIV
antiviral drugs. RDEA806 reproductive
toxicity data indicates that future
studies, including ...
Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
... in multiple indications with less
severe kidney
toxicity (nephrotoxicity) and nerve
toxicity (neurotoxicity)
than is commonly observed with ... and demonstrated that picoplatin has a manageable
toxicity in combination with 5-fluorouracil and ...
Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting
... Lymphoma: Clinical Efficacy without Cardiac
toxicity - Myron S. Czuczman, Roswell Park Cancer ... of total cumulative dose -- Cardiac
toxicity may also occur at lower cumulative doses (400 ... -- In patients with multiple myeloma, hematologic
toxicity (based on platelet count, absolute ...
Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
... Showing No Evidence of Increased
toxicity When Combined with Sorafenib
NEW YORK, Nov. 9 ... time to progression in both parts of the study.
toxicity Both, the 50 mg and 100 mg dose have been well ... daily dose of 50 mg or 100 mg
with no GI
toxicity was as follows: % with NO ...
Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
... Myelosuppression is usually the dose-limiting
toxicity with ALIMTA
therapy. Contraindication ALIMTA is ... folic acid and vitamin B12 died of
drug-related
toxicity following administration of ALIMTA alone. ALIMTA ... hematologic counts or maximum nonhematologic
toxicity from the
preceding cycle of therapy. Modify or ...
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
... NSCLC, while providing a
more favorable
toxicity profile and greater convenience. We look forward ... folic acid (350 to 1000 micrograms) to reduce
toxicity (for
full details see Summary of Product ... Dosage reduction is based upon the amount of
toxicity experienced by
the patient. Patients receiving ...
ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
... to enhance the activity and reduce
associated
toxicity of the widely used cancer chemotherapeutic agent ... to enhance the activity and reduce
associated
toxicity of the widely used cancer chemotherapeutic agent ... as drug metabolism and
bioavailability, excessive
toxicity and treatment resistance. More
information can be ...
Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
... to date suggest that hematologic events are common but manageable. Kidney
toxicity (nephrotoxicity) and nerve
toxicity (neurotoxicity) are less frequent and less severe than is commonly ...
USC Keck School of Medicine's Dr. Alan Epstein Receives Prestigious National Cancer Institute RAID Award for Breakthrough IL-2 Molecule Therapeutic
... patients, the application of IL-2 is severely limited by its significant
toxicity and resulting side effects, especially that of capillary leak syndrome ... Los Angeles-based biotechnology company developing innovative low
toxicity therapies for cancer, has licensed the molecule from USC . The ...
Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
... of the cancer in the surgical specimen) and a high incidence of Grade 3-4
toxicity to the upper gastrointestinal track necessitating prophylactic insertion ... response. A prophylactic feeding tube was not routinely used. Grade 3-4
toxicity in the first 15 patients included dehydration (n=5), loss of appetite ...
Horizon Therapeutics' HZT-501 Significantly Reduces Incidence of NSAID-Induced Upper Gastrointestinal Ulcers in Patients With Mild-to-Moderate Pain
... upper GI symptoms (e.g., dyspepsia, heartburn). Serious NSAID-induced GI
toxicity causes an estimated 16,500 deaths and more than 107,000 hospitalizations ... are reduced, NSAIDs often cause ulcers in the stomach. NSAID-induced GI
toxicity causes an estimated 16,500 deaths and more than 107,000 hospitalizations ...
Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients
... marrow function. There have been rare reports of serious kidney or liver
toxicity with GEMZAR treatment, sometimes fatal. Serious lung
toxicity has also been reported, sometimes fatal. If you think you are pregnant, ...
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
... results suggest that hematologic events are severe but manageable. Kidney
toxicity (nephrotoxicity) and nerve
toxicity (neurotoxicity) are less severe than is commonly observed with other ...
Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
... date suggest manageable hematologic adverse events with less severe kidney
toxicity (nephrotoxicity) and nerve
toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy ...
Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
... date suggest manageable hematologic adverse events with less severe kidney
toxicity (nephrotoxicity) and nerve
toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy ...
Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
... date suggest manageable hematologic adverse events with less severe kidney
toxicity (nephrotoxicity) and nerve
toxicity (neurotoxicity) than is commonly observed with other platinum chemotherapy ...
YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
... status of patients, are in sharp contrast to the dated speculation that
toxicity is a marker for efficacy of EGFR-targeting agents," said David Allan, ... at other nimotuzumab developers worldwide aimed at explaining the benign
toxicity profile of nimotuzumab given its established anti-tumour activity," said ...
American Oriental Bioengineering to Initiate a Phase One Clinical Trial in the United States of AOBO-001 Oral Capsule
... AOBO-001 on UI has
been evaluated in various in vitro and in vivo models.
toxicity of this
product was assessed through a series of
toxicity studies under the conditions
of GLP (Good Laboratory Practices) in China. ...
Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer
... FDA for the treatment of colorectal, lung, and other cancers. Due to its
toxicity and poor solubility, SN-38 cannot be administered systemically to cancer ... with labetuzumab-SN-38 should enhance the bioavailability and reduce the
toxicity of the clinically validated drug, irinotecan , " commented Cynthia L. ...
Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
... other indications, but is investigational for
treatment of acetaldehyde
toxicity associated with ethanol exposure in
ALDH2 deficient subjects.
(Logo: ... of 4-MP as a potential treatment of symptoms resulting from
acetaldehyde
toxicity in ALDH2 deficient subjects who drink alcohol. The
trial also sought to ...
Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma
... 3 to 4 thrombocytopenia occurred in 3 (5%)
patients. The most frequent
toxicity associated with Zevalin was
myelosuppression. Grade 3 to 4 neutropenia ... associated with pre-administration of
rituximab. The risk of hematologic
toxicity correlated with the degree of
bone marrow involvement prior to Zevalin ...
Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
... anti-tumor activity in multiple indications with less severe
kidney
toxicity (nephrotoxicity) and nerve
toxicity (neurotoxicity) than is
commonly observed with other platinum chemotherapy ...
PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
... which has been shown to be effective
in animal models in preventing
toxicity from exposure to chemical nerve
agents.
The randomized, ... includes manufacturing process
development, preclinical safety and
toxicity testing, submission of an
Investigational New Drug (IND) Application with ...
Landmark Study Demonstrates Potential of Radioimmunotherapy for Treatment of Indolent B-Cell Non-Hodgkin's Lymphoma
... median progression-free
survival (PFS) by approximately two years, with a
toxicity profile
comparable to that seen with Zevalin's use in approved ... associated with pre-administration of
rituximab. The risk of hematologic
toxicity correlated with the degree of
bone marrow involvement prior to Zevalin ...
Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
... for
a drug in this clinical setting, no significant bone marrow
toxicity was
observed.
In men with HRPC life expectancy can be as short as 18 ... Importantly for a drug in this clinical setting no
significant bone marrow
toxicity was observed in patients receiving
Alpharadin.
The full results of the ...
Precise Low-Dose Drug Monitoring Essential for Long-Term Kidney Transplant Success
... from long-term effects of
renal disease. Therefore, minimizing drug
toxicity over time is considered
one way to help improve long-term graft survival ... preserve quality of
life for transplant patients.
To minimize long-term
toxicity of transplant medications, physicians
frequently aim to taper down doses ...
CTI to Meet With the FDA to Discuss Filing of a Supplemental Biologics License Application for Zevalin(R)
... median progression-free
survival (PFS) by approximately two years, with a
toxicity profile
comparable to that seen with Zevalin's use in approved ... associated with pre-administration of
rituximab. The risk of hematologic
toxicity correlated with the degree of
bone marrow involvement prior to Zevalin ...
Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children
... to the accumulation in the
cells of a truncated protein, progerin, whose
toxicity is linked to the
presence of a fatty acid which remains fixed to the ... it is
eliminated in normal cells). In order to inhibit or block the
toxicity of
progerin, the researchers explored the path of synthesis of this ...
New Data Demonstrates 5-FU Personalized Chemotherapy Management (PCM(R)) Assay Provides Similar Performance to More Complicated Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
... simplified, personalized dose management
with the goal of minimizing
toxicity and maximizing the therapeutic benefit
of 5-FU treatment," said Salvatore ... to achieve optimal levels of 5-FU
can improve response rates and minimize
toxicity when compared to
standard-of-care dosing based on height and weight (known ...
Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
... that single agent perifosine showed encouraging
activity with manageable
toxicity in patients with relapsed/refractory
Waldenstroms macroglobulinemia. An ... patients with advanced
Waldenstrom's macroglobulinemia, and the manageable
toxicity profile seen
to date.
Michael Weiss, CEO of Keryx Biopharmaceuticals, ...
Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
... also exceeded 40 percent.
The study also demonstrated that the
toxicity profile of clofarabine
was predictable and manageable. Drug-related ... the kidneys. Concomitant use of
medications known to induce hepatic
toxicity should be avoided. Cardiac
disorders, including tachycardia, pericardial ...
Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
... anti-tumor activity in multiple indications with less severe
kidney
toxicity (nephrotoxicity) and nerve
toxicity (neurotoxicity) than is
commonly observed with other platinum chemotherapy ...